MARLTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics, a company dedicated to improving the lives of people with heart failure (HF), today announced that the National Medical Products Administration (NMPA) approved the application for market authorization of the Optimizer® CCM® device for patients with heart failure in the People’s Republic of China. HF impacts several million citizens in China, and approximately 500,000 new cases are diagnosed each year. For many of these patients who remain symptomatic after optimal pharmaceutical treatment, CCM therapy can now help them improve their symptoms and quality of life, including such basic activities as the ability to walk and exercise.
“Heart Failure has become a serious disease that severely affects the life span and quality of life of Chinese people, and it is also becoming a greater burden on our society due to growing population, complications in treatment, and challenges in dealing with relapses,” asserted Professor Zhang Shu from Fuwai Hospital. “The NMPA newly approved implantable CCM device from Impulse Dynamics, which is designed to improve the contractility of the myocardium, shines hope upon many heart failure patients of our country because this could become the treatment of choice by physicians.”
The Optimizer delivers CCM therapy, the company’s proprietary technology, to the heart. CCM therapy is the first approach of its kind designed to improve contraction of the heart, potentially allowing more oxygen-rich blood to reach the body. CCM therapy delivers precisely timed electrical pulses to the heart during the absolute refractory period of the beating cycle, just after the heart contracts. This breakthrough technology can improve the quality of life for patients who are no longer adequately responding to medications to manage their symptoms.
With an enduring presence in the Asia-Pacific region and an office in Beijing, Impulse Dynamics has undertaken scientific and clinical work for over ten years in China. “We are honored to receive approval from the NMPA after a rigorous evaluation process,” said Simos Kedikoglou, CEO of Impulse Dynamics. “Reaching this important milestone is another example of our long-term commitment to the clinical and commercial development of CCM therapy globally to help heart failure patients tackle this debilitating disease. We look forward to working closely with our long-term investors and partners, Henderson, CITIC, the Minth Group, and the recently added CR-CCT to launch this breakthrough, life-changing technology in China in the very near future.” Kedikoglou affirmed.
About Impulse Dynamics
Impulse Dynamics, based in Marlton, N.J., is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company has pioneered CCM therapy, which is delivered by the company’s Optimizer system, a breakthrough, FDA-approved treatment verified to progress the quality of life for heart failure patients. CCM therapy is a safe and effective minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them. To learn more, visit www.impulse-dynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.
###